Company Overview

Siva: The Hindu god of destruction and renewal

Siva Therapeutics is developing a cancer treatment which promises to be minimally invasive, to reduce harmful side effects, and to stimulate the immune system.  In addition to being more affordable, this technology could deliver faster results than current cancer treatments.  Siva achieves this treatment, termed Targeted Hyperthemia™, using SivaRod gold nanorods and a SivaLum™ infrared light device, which generates therapeutic heat emanating from within solid tumors.

Vision: To develop new cancer therapies that will save lives and not be dreaded by patients.

Mission: To develop a minimally-invasive, practical, safe, cost-effective, and efficacious device therapy for cancer using proprietary nanotechnology. To bring to market a product that will improve the efficacy of current cancer treatments and provide another tool for oncologists. To build a company that will gain and maintain a leadership position in the market for device therapies in cancer treatment.



SivaRods: each goold nanorod is approx 12x50nm
SivaRods: each gold nanorod is approx 12x50nm

According to the National Cancer Institute, cancer therapies are currently limited to surgery, radiation, and chemotherapy – all of which risk normal tissues or do not effectively eradicate the cancer. Innovations in nanotechnology aim to direct therapies directly at cancer cells, resulting in a targeted approach to treatment.

Siva Therapeutics is dedicated to becoming a leader in nanotechnology cancer therapies and we are rapidly developing innovative nanotechnology approaches for the treatment of cancer.

Targeting and Destroying Cancer Cells

Targeted Hyperthermia employs the systemic injection of SivaRods into the patient and illumination of the affected region with SivaLum.  The SivaRods concentrate in tumors, absorb the infrared light, and convert it into heat with very high efficiency.

Our technology employs: 1) the injection of a suspension of precision gold nanorods manufactured in a size, shape, and surface chemistry that cause them to selectively infiltrate growing, abnormally vascularized cancer tissues, and 2) targeted hyperthermia, in which infrared light is used to heat the nanorods, thereby destroying tumors while leaving surrounding tissue relatively unharmed.

Heat can destroy cancer cells. The challenge in using heat effectively has been to direct the heat to the tumors without damaging adjacent healthy tissue. Precision nanorods solve this problem. Nanorods are preferentially absorbed and retained by vascular tumors, and can direct heat to the tumor tissue.

Why SivaRods Therapy?

First, SivaRods nanorods can be manufactured with a higher degree of precision than other gold particles, resulting in a much narrower size distribution, and much higher dimension uniformity. Second, SivaRods nanorods absorb infrared radiation, and re-emit this radiation as heat, permitting photothermal heating of targeted tissues.  Conventional gold particles are roughly spherical in shape, and they absorb (and re-emit) shorter wavelengths of light, rather than infrared, eliminating photothermal capabilities.  In fact, the wavelength at which SivaRods nanorods absorb and re-emit light can be precisely tuned by regulating the length of the rods.

Improving Patient Outcome

Important to our work is the delivery of methods and technology that improve patient health and outcomes once faced with cancer.



Siva’s Targeted Hyperthermia™ Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research

AUSTIN, TEXAS, July 18, 2017 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md. FNL’s Nanotechnology Characterization Laboratory (NCL) – a partnership with the U.S. Food and Drug Administration …

Siva’s Targeted Hyperthermia™ Program Accepted by the Nanotechnology Characterization Laboratory

AUSTIN, TEXAS, August 29, 2016 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has been accepted has been accepted for characterization by the Nanotechnology Characterization Laboratory (NCL) in Frederick, Maryland. The NCL is a national resource which facilitates the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By …

Siva Therapeutics Publishes in the Journal of Nanomaterials

BOULDER, COLORADO, August 7, 2014 – Siva Therapeutics has had a manuscript accepted for publication in the Journal of Nanomaterials.  The forthcoming paper, entitled “Photothermal therapy using gold nanorods and near-infrared light in a murine melanoma model increases survival and decreases tumor volume” by Mary Popp and colleagues, describes Siva’s approach to photothermal monotherapy for …


Chief Executive Officer – Len Pagliaro, PhD, has 18 years of experience with successful commercialization of biotechnology products, services, and licensing, following an academic career. He has managed R&D and business development teams, and brought product lines from concept through commercialization to acquisition. A small molecule oncology project he led was successfully partnered with TopoTarget, and is now in the clinic. Len managed the P&L for a business unit of Thermo Fisher Scientific selling tools for drug discovery before co-founding Siva. He is responsible for overall corporate strategy and financing.

Co-Founder and Counsel – Steve Kregstein, received a JD, cum laude degree from Harvard Law School and has practiced law for over 30 years in law firms and public and private corporations. He co-founded and served as Chief Legal Officer and Vice Chairman of ClearVision Laser Centers, a national network of laser vision correction centers. ClearVision was formed with a total angel investment of $3M. These early investors realized a 12X return four years later when all shareholders sold their interests in the company for $60M. His in-house legal experience with medical device companies includes service as Vice President of Sound Surgical Technologies, a manufacturer of ultrasound devices, and as Corporate Counsel for Terumo BCT, an international manufacturer of blood component technologies.

Chief Operating Officer – Colin Shepherd, PhD, MBA, received a BS in Biotechnology from the University of Kentucky (2000), a PhD in Genetics from Iowa State University (2007), and an MBA from Iowa State University (2008). He founded AimsBio Inc. in 2006 and commercialized a novel amino acid bioassay that was used by clients in a variety of industries. From 2009 to 2011 he performed as COO of PhylloTech LLC where he led the overall business development and financial operations. Colin manages all operations and early stage R&D as well as finances.